Evaluation of herb-drug interaction of ambrisentan with shikonin based on UPLC-MS/MS

References

• Albreht A, Vovk I, Simonovska B, Srbinoska M. 2009. Identification of shikonin and its ester derivatives from the roots of Echium italicum L. J Chromatogr A. 1216(15):3156–3162.
   PubMed Web of Science ®Google Scholar
• Assimopoulou AN, Karapanagiotis I, Vasiliou A, Kokkini S, Papageorgiou VP. 2006. Analysis of alkannin derivatives from Alkanna species by high-performance liquid chromatography/photodiode array/mass spectrometry. Biomed Chromatogr. 20(12):1359–1374.
   PubMed Web of Science ®Google Scholar
• Barst RJ. 2007. A review of pulmonary arterial hypertension: role of ambrisentan. Vasc Health Risk Manag. 3(1):11–22.
   PubMedGoogle Scholar
• Croxtall JD, Keam SJ. 2008. Ambrisentan. Drugs. 68(15):2195–2204.
   PubMed Web of Science ®Google Scholar
• Elshaboury SM, Anderson JR. 2013. Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes. Patient Prefer Adherence. 7:401–409.
   PubMed Web of Science ®Google Scholar
• Enderle Y, Meid AD, Friedrich J, Grunig E, Wilkens H, Haefeli WE, Burhenne J. 2015. Dried blood spot technique for the monitoring of ambrisentan, bosentan, sildenafil, and tadalafil in patients with pulmonary arterial hypertension. Anal Chem. 87(24):12112–12120.
   PubMed Web of Science ®Google Scholar
• Enderle Y, Witt L, Wilkens H, Grunig E, Haefeli WE, Burhenne J. 2017. Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension. J Pharm Biomed Anal. 143:291–298.
   PubMed Web of Science ®Google Scholar
• Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, et al. 2005. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 46(3):529–535.
   PubMed Web of Science ®Google Scholar
• Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. 2008. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 371(9630):2093–2100.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez S, Rico E, Casal E, Grisalena A, Alcaraz E, King N, Leal N, Navarro I, Campanero MA. 2018. Bionalytical validation study for the determination of unbound ambrisentan in human plasma using rapid equilibrium dialysis followed by ultra performance liquid chromatography coupled to mass spectrometry. J Pharm Biomed Anal. 150:427–435.
   PubMed Web of Science ®Google Scholar
• Harrison B, Magee MH, Mandagere A, Walker G, Dufton C, Henderson LS, Boinpally R. 2010. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. Clin Drug Investig. 30(12):875–885.
   PubMed Web of Science ®Google Scholar
• Hu Y, Jiang Z, Leung KS, Zhao Z. 2006. Simultaneous determination of naphthoquinone derivatives in Boraginaceous herbs by high-performance liquid chromatography. Anal Chim Acta. 577(1):26–31.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. 2004. Treatment of pulmonary arterial hypertension. N Engl J Med. 351(14):1425–1436.
   PubMed Web of Science ®Google Scholar
• Lukram OK, Sharma R. 2014. High-performance liquid chromatography tandem mass spectrometry method for quantification of endothelin receptor antagonist drug, ambrisentan, in human plasma and its application in a pharmacokinetic study. Biomed Chromatogr. 28(8):1147–1155.
   PubMed Web of Science ®Google Scholar
• Markert C, Hellwig R, Burhenne J, Hoffmann MM, Weiss J, Mikus G, Haefeli WE. 2013. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. Eur J Clin Pharmacol. 69(10):1785–1793.
   PubMed Web of Science ®Google Scholar
• Nirogi R, Kandikere V, Komarneni P, Aleti R, Padala N, Kalaikadhiban I. 2012. LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study. Biomed Chromatogr. 26(10):1150–1156.
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK. 1987. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 107(2):216–223.
   PubMed Web of Science ®Google Scholar
• Richards DB, Walker GA, Mandagere A, Magee MH, Henderson LS. 2009. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol. 49(6):719–724.
   PubMed Web of Science ®Google Scholar
• Rubin LJ. 1997. Primary pulmonary hypertension. N Engl J Med. 336(2):111–117.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Dufton C, Gerber MJ. 2005. Ambrisentan for pulmonary arterial hypertension. Future Cardiol. 1(4):425–432.
   PubMedGoogle Scholar
• Sankawa U, Ebizuka Y, Miyazaki T, Isomura Y, Otsuka H. 1977. Antitumor activity of shikonin and its derivatives. Chem Pharm Bull. 25(9):2392–2395.
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. 2011. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 8(8):443–455.
   PubMed Web of Science ®Google Scholar
• Tabata M, Mizukami H, Naoe S, Konoshima M. 1975. Antimicrobial activity of Lithospermum erythrorhizon callus cultures. Yakugaku Zasshi. 95(11):1376–1379.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Uchida S, Hakamata A, Miyakawa S, Odagiri K, Inui N, Watanabe H, Namiki N. 2020. Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. Pharmazie. 75(6):236–239.
   PubMed Web of Science ®Google Scholar
• Tang S, Chen A, Zhou X, Zeng L, Liu M, Wang X. 2017. Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay. Toxicol Lett. 281:74–83.
   PubMed Web of Science ®Google Scholar
• van de Velde D, Bahmany S, Hitzerd E, van Domburg B, Versmissen J, Danser AHJ, Koch BCP. 2020. Simultaneous quantification of ambrisentan, macitentan and sitaxentan in human plasma using UPLC-MS/MS. Biomed Chromatogr. 34(3):e4787.
   PubMed Web of Science ®Google Scholar
• Vizza CD, Fedele F, Pezzuto B, Rubin LJ. 2012. Safety and efficacy evaluation of ambrisentan in pulmonary y hypertension. Expert Opin Drug Saf. 11(6):1003–1011.
   PubMed Web of Science ®Google Scholar
• Wang WJ, Bai JY, Liu DP, Xue LM, Zhu XY. 1994. The antiinflammatory activity of shikonin and its inhibitory effect on leukotriene B4 biosynthesis. Yao Xue Xue Bao. 29(3):161–165.
   PubMedGoogle Scholar
• Yokoyama Y, Tomatsuri M, Hayashi H, Hirai K, Ono Y, Yamada Y, Todoroki K, Toyo'oka T, Yamada H, Itoh K. 2014. Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension. J Pharm Biomed Anal. 89:227–232.
   PubMed Web of Science ®Google Scholar